]>
IRCT20170417033483N2 IRCT 2018-02-13 Kurdistan university of Medical Sciences Comparison the effect of two days interval amikacin with standard therapy in treatment of urinary tract infection Comparison the effect of two days interval amikacin with standard therapy in treatment of urinary tract infection 2017-05-22 anticipated 200 Complete https://irct.ir/trial/25810 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Patients with inclusion criteria are randomly assigned to blocks of 20 in one of the two new treatment groups and the two control groups (routine treatment), Blinding description: After determining the treatment group, the treatment is given to each group based on the protocol (one group of moropenem and one group of amikacin). The drug is administered via micro-nutrition. The new treatment group receives 48 hours of amikacin at 3mg / kg / Q48 hours. The control group receives 1 μg / TDS of morophen every 8 hours. Blind for each group is injected through the microscope at intervals of 8 hours, in the intervention group, additional injections contain distilled water, which is poured into normal saline containing microscope. Medicines are placed in the patient basket by category. And the nurse will run the daily basket in accordance with its instructions. Given that the assessor, the laboratory and patient are not aware of any grouping. 3 UTI. Intervention 1: Intervention group ESBL: Each 48 hours of amikacin is given 3mg / kg / Q48 hours for 7 days, and then treatment of Ofloxacin 300 mg twice daily for 7 days is continued. Intervention 2: ESBL control group: INn ESBL control group patients Maropenem is given at a dose of 1 g three times a day for one week, followed by treatment with ofloxacin 300 mg twice daily for 7 days. Intervention 3: Control group NON ESBL: In non-ESBL control group patients Maropenem is given at a dose of 1 g three times a day for one week, followed by treatment with ofloxacin 300 mg twice daily for 7 days. Intervention 4: Non ESBL intervention group: Each 48 hours of amikacin is given 3mg / kg / Q72 hours for 7 days, then treatment with ofloxacin 300 mg twice daily for 7 days. Undecided - It is not yet known if there will be a plan to make this available
public hero azizzadeh
Kurdistan University of Medical Sciences, pasdararn street , Sanandaj
sanandaj Iran (Islamic Republic of) 666147 - 13446 +98 87 3366 4645 h.azizzadeh@muk.ac Kurdistan University of Medical Sciences scientific Dr.behzad mohsenpour
Kurdistan University of Medical Sciences, Pasdaran Boulevard, Sanandaj, Kurdistan
sanandaj Iran (Islamic Republic of) 666147 - 13446 +98 87 3366 4645 behzadmohsenpour@yahoo.com kurdistan University of Medical Sciences Iran (Islamic Republic of) Patients with symptoms of burning up urine Patients with frequent urinary symptoms Patients with urinary symptoms and fever no limit no limit Both Use of antibiotics over the last week Stage I and above CKD pregnancy septic shock use of immuno suppressive drugs Increased patient creatinine by more than 3 or more than 50% relative to the original creatinine during treatment N39 Urinary tract infection, site not specified Treatment - Drugs Treatment - Drugs Treatment - Drugs Treatment - Drugs Intervention group ESBL: Each 48 hours of amikacin is given 3mg / kg / Q48 hours for 7 days, and then treatment of Ofloxacin 300 mg twice daily for 7 days is continued. ESBL control group: INn ESBL control group patients Maropenem is given at a dose of 1 g three times a day for one week, followed by treatment with ofloxacin 300 mg twice daily for 7 days. Control group NON ESBL: In non-ESBL control group patients Maropenem is given at a dose of 1 g three times a day for one week, followed by treatment with ofloxacin 300 mg twice daily for 7 days. Non ESBL intervention group: Each 48 hours of amikacin is given 3mg / kg / Q72 hours for 7 days, then treatment with ofloxacin 300 mg twice daily for 7 days. Urinary tract infection(UTI). Timepoint: 7 days after the start of treatment, intravenous and oral treatment phase (7 days. Method of measurement: Urine analysis and urina culture. Clinical symptoms of UTI. Timepoint: 48 hours and 1 week after the end of therapy with intravenous and oral treatment. Method of measurement: By patient symptoms and clinical findings. Adverse Drug Reactions. Timepoint: 48 hours and 1 week after treatment and at the end of intravenous and oral treatment. Method of measurement: Clinical symptoms and examination findings, laboratory. Kurdistan university of Medical Sciences Approved 2016-10-30 University of Kurdestan Medical Sciences, Faculty of Medicine Sanandaj, Kurdistan-Kurdistan-Iran Iranian Revolutionary Guards University of Medical Sciences sanandaj Kurdistan Iran (Islamic Republic of)